Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test – Investor's Business Daily

Business News

  1. Annovis Bio Stock Crashes After Much-Hyped Alzheimer’s Drug Flops In Midstage Test  Investor’s Business Daily
  2. UPDATE: Annovis touts Alzheimer’s drug as better than Biogen, but failed data makes for a bleak day at the stock market  FierceBiotech
  3. Annovis Bio (ANVS) loses nearly half after presenting Alzheimer’s drug data at AAIC 2021  Seeking Alpha
  4. Here’s Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday  Motley Fool
  5. ANVS Stock Fell Over 57% Intraday: Why It Happened  Pulse 2.0
  6. View Full Coverage on Google News

Source: Business News

/by